Results 61 to 70 of about 18,187,223 (191)

Advancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translation

open access: yesMedComm, Volume 7, Issue 10, October 2026.
In vivo CAR‐T cell generation directly engineers endogenous T cells using pre‐manufactured gene delivery vectors that target T cells and deliver CAR‐encoding genetic material. The resulting CAR‐T cells expand in vivo and mediate antigen‐specific cytotoxicity.
Zhenxin Bai   +6 more
wiley   +1 more source

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

open access: yesBritish Journal of Haematology, Volume 209, Issue 4, Page 1619-1628, October 2026.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini   +15 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn   +17 more
wiley   +1 more source

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

open access: yesAging and Cancer, Volume 7, Issue 3, Page 109-124, September 2026.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang   +3 more
wiley   +1 more source

Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports

open access: yesCancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Reports of immune checkpoint inhibitor (ICI) therapy‐associated immune‐related adverse events (irAEs) exhibit considerable heterogeneity, particularly when comparing data from clinical trials and real‐world observational studies. Methods We conducted a systematic review of real‐world observational studies (case reports and series ...
Shea‐Lee Godin   +4 more
wiley   +1 more source

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

open access: yes, 2014
Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with generally poor clinical outcome. Currently 50% of PTCL cases are not classifiable: PTCL-not otherwise specified (NOS).
Connors, J.M.   +111 more
core   +2 more sources

Using Murine Models to Investigate Tumor–Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma

open access: yesFrontiers in Oncology, 2017
The role of the tumor microenvironment in leukemias and lymphomas is well established, yet the intricacies of how the malignant cells regulate and influence their non-malignant counterparts remain elusive.
Christine E. Cutucache, Tyler A. Herek
doaj   +1 more source

TET2 as a Context‐Dependent Epigenetic Integrator in Clonal Hematopoiesis, Inflammation, Cancer, and Immunotherapy

open access: yesCell Biochemistry and Function, Volume 44, Issue 8, August 2026.
ABSTRACT Ten‐Eleven Translocation 2 (TET2) is an Fe(II)‐ and α‐ketoglutarate‐dependent dioxygenase that initiates active DNA demethylation by oxidizing 5‐methylcytosine (5mC). Beyond this enzymatic role, TET2 links DNA methylation dynamics with chromatin regulation, cellular metabolism, immune‐cell identity, and treatment response in a context ...
XiaoJie Liu   +5 more
wiley   +1 more source

Angioimmunoblastic T-cell lymphoma presenting with an acute serologic Epstein-Barr virus profile

open access: yesHematology Reports, 2015
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma typically characterized by prominent lymphadenopathy and B-symptoms at the time of presentation, polyclonal hypergammaglobulinemia, autoimmune hemolysis and frequent ...
Timothy Beer, Patrick Dorion
doaj   +1 more source

Safety and Effectiveness of Denileukin Diftitox‐cxdl in Patients With Relapsed/Refractory Peripheral T‐Cell Lymphoma and Cutaneous T‐Cell Lymphoma: An All‐Case Post‐Marketing Study in Japan

open access: yesCancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Introduction Denileukin diftitox (DD)‐cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin‐2, is a treatment for peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma (CTCL). Previous trials have enrolled a limited number of patients, and there is a need to evaluate DD‐cxdl in a more diverse population ...
Tatsuro Jo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy